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Abstract
Eosinophils are granule-containing leukocytes which develop in the bone marrow. For many years, eosinophils have been
recognized as cytotoxic effector cells, but recent studies suggest that they perform additional immunomodulatory and homeo-
static functions. Autophagy is a conserved intracellular process which preserves cellular homeostasis. Autophagy defects have
been linked to the pathogenesis of many human disorders. Evidence for abnormal regulation of autophagy, including decreased
or increased expression of autophagy-related (ATG) proteins, has been reported in several eosinophilic inflammatory disorders,
such as Crohn’s disease, bronchial asthma, eosinophilic esophagitis, and chronic rhinosinusitis. Despite the increasing extent of
research using preclinical models of immune cell-specific autophagy deficiency, the physiological relevance of autophagic
pathway in eosinophils has remained unknown until recently. Owing to the increasing evidence that eosinophils play a role in
keeping organismal homeostasis, the regulation of eosinophil functions is of considerable interest. Here, we discuss the most
recent advances on the role of autophagy in eosinophils, placing particular emphasis on insights obtained in mouse models of
infections and malignant diseases in which autophagy has genetically dismantled in the eosinophil lineage. These studies pointed
to the possibility that autophagy-deficient eosinophils exaggerate inflammation. Therefore, the pharmacological modulation of
the autophagic pathway in these cells could be used for therapeutic interventions.
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Introduction
Eosinophils are granulocytes which are characterized by their
avidity for the acidic dye eosin [1]. Relatively few mature
eosinophils are found in the peripheral blood of healthy
humans (less than 400 per mm3) [2]. Moreover, under homeo-
static conditions, eosinophils reside primarily in all regions of
the digestive system except the esophagus [3]. Eosinophils are
also present in lymphoid organs such as thymus, lymph nodes,
and spleen. A physiological infiltration of eosinophils is also
seen in non-lymphoid organs such as adipose and mammary
gland tissues as well as in the uterus [4]. Moreover, the so-
called regulatory eosinophils have been observed in normal
human and mouse lungs [5]. In response to inflammatory
stimuli, eosinophil differentiation in the bone marrow is in-
creased and eosinophils migrate towards inflammatory tissues
where their lifespan is prolonged [6, 7]. When blood eosino-
phil numbers exceed 400 per mm3, the term eosinophilia ap-
plies. A threshold of 1500 eosinophils per mm3 is usually
employed to define blood hypereosinophilia [8]. A cytokine-
independent eosinophilia is caused by genetic changes within
the eosinophil lineage, and the resulting diseases are classified
as primary or intrinsic eosinophilic disorders [9].
The most typical eosinophil characteristic which discrimi-
nates them from other granulocytes (neutrophils and baso-
phils) is the presence of large specific granules in the cyto-
plasm [10, 11]. A significant amount of mediators, including
cytotoxic cationic proteins, cytokines, chemokines, and
growth factors, are preformed and stored within eosinophil
specific granules, where they are available for a rapid,
stimulus-dependent release [12, 13]. Other characteristic or-
ganelles in eosinophils are primary granules, known to contain
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the Charcot-Leyden crystal protein (also known as galectin-
10), and lipid bodies, which are production sites of inflamma-
tory lipid mediators such as cysteinyl leukotrienes, thrombox-
anes, and prostaglandins [14, 15].
Contrary to neutrophils, which are essential for host de-
fense, pharmacological or genetic depletion of eosinophils
does not cause evident functional consequences [16].
Nevertheless, the fact that eosinophil lineage in all vertebrates
survived the evolution pressure over several thousands of
years demonstrates the importance of eosinophils in health
and disease [17]. While eosinophils have been traditionally
perceived as cytotoxic effector cells, recent studies have re-
vealed their additional immunomodulatory and homeostatic
activities. The role of eosinophils in immunity is still a matter
of dispute and remains to be ambiguously defined. Preclinical
mouse models mimicking human eosinopenia [18, 19] and
hypereosinophilia [20, 21] as well as the ability to specifically
knockout genes in the eosinophil lineage [22] allow to inves-
tigate the potential roles of eosinophils in health and disease.
Moreover, targeted anti-eosinophil therapies allow to draw
conclusions regarding the contribution of eosinophils for
physiological and pathophysiological processes in humans
[23].
Autophagy
Macroautophagy (hereafter referred to as autophagy) is a
highly dynamic intracellular degradation system by which cy-
toplasmic constituents are delivered to lysosomes for degra-
dation [24, 25]. The main morphological feature of autophagy
is the biogenesis of autophagosome, a unique double-
membraned vesicle which encloses parts of the cytoplasm.
The fusion between autophagosomes and lysosomes results
in the formation of auto(phago)lysosomes, in which cargo is
degraded by a number of hydrolytic enzymes. Breakdown
products are then returned to the cytosol and reused [24, 25]
(Fig. 1a).
The autophagic pathway is a central component of cellular
stress response, and it assures a proper biological adaptation to
the continually changing environment [26]. In general, au-
tophagy has two principal functions: (1) provision of essential
building blocks under the conditions of nutrient or energy
deprivation and (2) maintenance of cellular homeostasis by
elimination of damaged macromolecules and organelles
[27]. Therefore, autophagy is a process which keeps individ-
ual cells in a healthy state. Any perturbation is expected to
cause, or at least to contribute, to the pathogenesis of diseases.
For instance, autophagy has been implicated in several pathol-
ogies, particularly neurodegeneration, cancer, inflammation,
and infectious diseases [28–30]. Moreover, work in the last
two decades has also demonstrated that autophagy is critical
for multiple functions of the immune system such as removal
of pathogens, differentiation of immune cells, antigen presen-
tation, and regulation of inflammatory responses [31, 32].
The autophagic pathways have been characterized in ex-
cellent reviews, and general roles of autophagy in the regula-
tion of immunity have been covered elsewhere [31–37].
Therefore, we only introduce the canonical autophagy path-
way that requires autophagy-related (ATG) proteins. In the
following, we discuss recently published work on the involve-
ment of autophagy in eosinophil-associated diseases and re-
view experimental work on the role of ATG proteins in eosin-
ophil development and functions.
The molecular mechanism of autophagy
Understanding of the molecular mechanism of autophagy has
progressively advanced since the identification of ATG genes.
Inmammals, the protein machinery is organized into function-
al units which are required for autophagosome biogenesis.
Upon autophagy induction, the ULK complex (consisting of
the protein kinase ULK1/2, ATG13, ATG101 and FIP200) is
generated, arising from regions where ATG9 vesicles line up
with the endoplasmic reticulum (ER) [38, 39]. ULK complex
is required for the recruitment and activation of the class III
phosphatidylinositol 3-kinase (PI3K) complex (consisting of
the lipid kinase VPS34, VPS15, ATG14, and Beclin 1), local-
ly producing phosphatidylinositol 3-phosphate (PI3P) [39,
40]. The function of PI3P could be the formation of a
phagophore membrane by modifying the composition of the
ER membrane and recruitment of PI3P effectors [41]. Two
ubiquitin-like conjugation systems are essential for proper
elongation and closure of the phagophore membrane. The
ATG12-ATG5-ATG16L1 complex is located mainly on the
outer side of the phagophore membrane, followed by its dis-
assembly upon autophagosome completion [41]. In the next
step, the ATG12-ATG5-ATG16L1 complex promotes
microtubule-associated protein light chain 3 (LC3) conjuga-
tion with phosphatidylethanolamine (PE) on the expanding
phagophore membrane. Lipidated LC3 (LC3-II) serves as a
commonly used marker for detection of double-membrane
organelles owing to its integration into both the inner and
outer autophagosomal membrane [42, 43] (Fig. 1b).
Autophagic pathway is strongly regulated by the activity of
mechanistic target of rapamycin complex 1 (mTORC1),
which senses the levels of nutrients and growth factors [44].
A strong trigger for autophagy induction is the lack of amino
acids, leading to inhibition ofmTORC1 activity and activation
of suppressed ULK complex [45, 46]. Another central autoph-
agy regulator is an AMP-activated protein kinase (AMPK), a
sensor of metabolic, oxidative, and genomic stress [47]. Under
the conditions of inadequate glucose levels, hypoxia or DNA
damage, the AMPK activity is induced and promotes autoph-
agy either bymTORC1 inhibition or direct phosphorylation of
ULK complex [48, 49]. In addition, class I PI3K responds to
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growth factor signaling and suppresses autophagy by positive-
ly regulating the mTORC1 activity [50] (Fig. 1c). In contrast,
class III PI3K (VPS34) forms a protein complex and produces
the phospholipid PI3P, contributing to the initiation and pro-
gression of autophagy [50].
The protein p62 (sequestosome 1/SQSTM1) is a specific
substrate for autophagy, and reduced autophagy is often relat-
ed to excessive accumulation of p62 [41]. Besides, p62 selec-
tively delivers ubiquitinated proteins to the phagophore mem-
brane following the interaction with LC3-II [51, 52]. Finally,
fusion between autophagosomes and lysosomes results in
degradation of the auto(phago)lysosomal contents by hydro-
lytic enzymes [53]. Despite the extensive involvement of
ATG proteins in autophagy machinery, it has been shown that
many ATGs also exhibit additional non-autophagic functions
that are discussed elsewhere [54, 55].
Regulation of the function of immune cells by
autophagy
The discovery of the ATG proteins was followed by in-depth
investigation of the autophagy machinery and its critical in-
volvement in the functioning of the immune system became
evident [32]. The most direct approach of autophagy-
dependent microbial removal is through xenophagy, a selec-
tive form of autophagy in which intracellular pathogens are
targeted for autophagosomal sequestration [56–60]. Two pos-
sible mechanisms for the recognition of intracellular microbes
by the autophagy machinery have been suggested. During
xenophagy, the cytosolic bacteria are tagged by ubiquitin mol-
ecules and recognized by p62, which recruits the LC3-positive
phagophores to capture the bacteria [61, 62]. Alternatively,
ubiquitin is conjugated to host proteins on Salmonella-
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Fig. 1 Schematic representation of the mammalian autophagy
pathway. a Upon initiation of autophagy, a small portion of the
cytoplasm is enclosed by the phagophore (also known as isolation
membrane) which may originate from an ER-based structure.
Elongation of the phagophore is followed by the autophagosome
completion and its fusion with the lysosome, where the engulfed
contents are degraded within the autolysosome. b ULK and class III
PI3K (VPS34) protein complexes are required for the phagophore
initiation. In addition, ATG12 and LC3 ubiquitin-like conjugation
systems are necessary for subsequent elongation of the phagophore and
its closure. c Autophagy is largely regulated by the activity of mTORC1,
which reflects cellular nutritional status. Sufficient amounts of amino
acids and growth factors suppress autophagy due to the inactivation of
ULK complex by mTORC1 activity. On the contrary, mTORC1 activity
is inhibited by cellular stress such as energy deprivation, DNA damage,
and hypoxia, leading to the release and activation of the ULK complex
which initiates the formation of autophagosomes
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containing endosomes and binds with ATG16L1 indepen-
dently of LC3-ubiquitin interaction through adaptor proteins
[63]. In addition, p62 is able to deliver the ribosomal protein
precursor Fau to autolysosomes where it is metabolized into
bactericidal peptides. As a consequence, autophagic organ-
elles are endowed with unique antimicrobial properties [64].
Autophagy is involved in the regulation of inflammatory
responses. For example, it can suppress the immune response
through the inhibition of inflammasomes, leading to reduced
activation of caspase-1 and secretion of the pro-inflammatory
cytokines IL-1β in IL-18 [65–69]. Moreover, autophagy has
an influence on the homeostasis, survival, activation, prolifer-
ation, and differentiation of multiple cells of the immune sys-
tem such as natural killer (NK) cells, macrophages, dendritic
cells (DCs), as well as T and B cells. For instance, autophagy
contributes to the maturation and antiviral activities of NK
cells [70, 71]. Autophagy also participates in antigen presen-
tation by DCs, forming a link between the innate and adaptive
immune systems. The autophagic sequestration promotes the
delivery and presentation of endogenous antigens on major
histocompatibility complex (MHC) class II molecules,
resulting in enhanced CD4+ T helper cell responses [72, 73].
On the contrary, autophagy enhances internalization and deg-
radation of MHC class I molecules, leading to compromised
MHC class I antigen presentation and attenuated response of
cytotoxic CD8+ T cells [74]. Previous reports have also dem-
onstrated the significance of autophagy for the development,
survival and effector functions of T [75–79] and B cells
[80–84]. Furthermore, it has been suggested that autophagy
supports the release of β-hexosaminidase and histamine from
mast cells [85]. The involvement of autophagy has also been
demonstrated in neutrophil differentiation [86, 87] and effec-
tor functions [88].
In contrast to other cells of the immune system, the rele-
vance of autophagy and ATG proteins for the biology of eo-
sinophils has long remained elusive. However, insightful ev-
idence was recently generated from experimental mouse
models in which Atg5 was specifically depleted in the eosin-
ophil lineage, resulting in eosinophil-specific autophagy defi-
ciency [89]. As discussed below, these models allowed testing
the function of eosinophils under in vitro conditions in the
presence and absence of ATG5. Moreover, these mouse lines
were used in preclinical models of bacterial infection and pri-
mary hypereosinophilic disease.
Role of autophagy in eosinophilic diseases
Interest in the role of autophagy in immunity was partially
driven by the association of ATG genes with inflammatory
disorders. Genetic alterations in autophagy may be hereditary,
predisposing individuals to autoimmune, autoinflammatory,
or infectious diseases. The involvement of autophagy has
been observed in several eosinophilic inflammatory diseases,
such as Crohn’s disease (CD), bronchial asthma, eosinophilic
esophagitis (EoE), and chronic rhinosinusitis (CRS). Study
models of eosinophilic inflammatory diseases and observed
results are summarized in Table 1.
Crohn’s disease (CD)
Inflammatory bowel disease (IBD) encompasses two types of
chronic inflammatory disorders of the gastrointestinal tract,
CD, and ulcerative colitis (UC) [90]. Accumulating evidence
suggests that inflammatory conditions in the intestine result
from the abnormal immune response to enteric microbes in
genetically predisposed individuals [91]. Genetic studies of
IBD have made great progress since 242 risk loci have been
identified through genome-wide association studies (GWAS)
associated with the presence of IBD, highlighting some major
disease-associated pathways [92]. Moreover, NOD2 has been
identified as a major susceptibility gene [93, 94].
Two genes involved in autophagy, ATG16L1 and
immunity-related GTPase M (IRGM), have been strongly as-
sociated with CD but not with UC, suggesting that autophagy
is involved in the pathogenesis of CD [91]. A GWAS reported
a single-nucleotide polymorphism (SNP) encoding a suscep-
tibility variant of ATG16L1 gene (rs2241880, Thr300Ala)
which is associated with a significant risk for CD [95, 96].
Since its discovery, SNP rs2241880 remained one of the most
clinically important variants in CD and a large number of
subsequent association studies have replicated the strong as-
sociation of this genetic variation with CD [97–100]. The
ATG16L1 Thr300Ala variant is associated with an excessive
production of the pro-inflammatory cytokines IL-1β and IL-6
that drive the chronic inflammation observed in CD [101].
Moreover, this variant is more susceptible to cleavage by cas-
pase-3, resulting in compromised clearance of Yersinia (Y.)
enterocolitica and Salmonella (S.) typhimurium, as well as
elevated cytokine production [102, 103].
IRGM has been demonstrated to induce autophagy and
generate large autolysosomal organelles as a mechanism to
inhibit the survival of intracellular Mycobacterium (M.)
tuberculosis [104]. Recently, it has been reported that IRGM
physically interacts with ULK1 and Beclin 1, promoting their
assembly and thus controlling the arrangement of autophagy
initiation complexes. In addition, IRGM forms a molecular
complex with NOD2 and ATG16L1, modulating autophagic
responses to pathogens [105]. A significant association has
been reported between CD in various ethnic cohorts and se-
quence variants in the IRGM gene (SNPs rs13361189,
rs4958847, and rs10065172) [100, 106–109]. The SNP
rs13361189 was found to increase the risk of CD clinical
sub-phenotypes such as ileal disease, perianal disease, and
intestinal resection [110]. Interestingly, a gene-gene interac-
tion analysis showed a significant two-way interaction
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between SNP rs2241880 (ATG16L1) and rs10065172
(IRGM), suggesting that ATG16L1 and IRGM work jointly
toward CD pathogenesis [111].
Further insight into the role of ATG16L1 was obtained
using genetically modified mice. Mice lacking Atg16L1 in
hematopoietic cells revealed a strong susceptibility to acute
colitis induced by dextran sulfate sodium, implying that
Atg16L1 protects mice from intestinal inflammation [65].
Atg16L1 is also important in the biology of epithelial Paneth
cells as Atg16L1-knockout Paneth cells demonstrated a defec-
tive granule exocytosis which might alter the intestinal micro-
biota [112]. However, despite the intense investigations of the
IBD pathogenesis, the role of autophagy in eosinophils has
not been addressed yet.
Bronchial asthma
Asthma is a heterogeneous disease characterized by chronic
airway inflammation. Patients develop a variety of respiratory
symptoms such as wheeze, breath shortness, chest tightness,
cough, and expira tory ai r f low l imi ta t ion [113] .
Polymorphisms in ATG genes have suggested that a genetic
predisposition may increase the chance to develop asthma.
Since autophagy has been shown to regulate immune re-
sponses and inflammation, a possible association of genetic
variants of ATG5 and ATG7 genes with childhood asthma was
investigated. Two ATG5 SNPs, rs12201458 and rs510432,
were significantly associated with asthma, the latter being
functionally relevant by enhancing promotor activity [114].
Moreover, ATG5 gene expression was upregulated in nasal
epithelial cells isolated from asthmatics with acute symptoms
[114]. Similarly, the expression of ATG proteins (LC3-II,
ATG4, ATG5-ATG12, ATG7) as well as the number of au-
tophagic vacuoles was also increased in lung tissue from
Table 1 The involvement of autophagy and ATG proteins in
eosinophilic inflammatory diseases. Evidence for dysregulated
autophagy has been reported in Crohn’s disease (CD), asthma,
eosinophilic esophagitis (EoE) and chronic rhinosinusitis (CRS).
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patients with chronic obstructive pulmonary disease (COPD)
[115]. Another study investigated the potential association of
SNPs in ATG genes (ULK1, SQSTM1, MAP1LC3B, BECN1,
and ATG5) with asthma. SNP rs12212740 of ATG5 exhibited
a positive association with asthma [116]. Examination of
bronchial tissue from asthmatic patients demonstrated an in-
creased number of autophagosomes in fibroblasts and epithe-
lial cells compared with healthy individuals [116].
Similarly to structural cells, autophagy levels in sputum
granulocytes, blood leukocytes, and blood eosinophils from
patients with severe asthma were significantly increased as
compared with subjects with non-severe asthma and healthy
controls [117]. Interestingly, autophagy was induced in isolat-
ed blood eosinophils and human eosinophil-like (HL-60) cells
in response to IL-5 treatment. To confirm that IL-5 induced
autophagy rather than inhibited autophagosome degradation,
inhibitors were usedwhich blocked autolysosome degradation
or fusion of autophagosome with lysosome [117]. These find-
ings stimulated investigations in ovalbumin (OVA)-specific
mouse model of allergic asthma [118]. OVA-challenged mice
exhibited an increased expression of LC3-II in lung homoge-
nates and a higher abundance of autophagosomes in cells of
the bronchoalveolar lavage fluid (BALF), particularly in eo-
sinophils. The eosinophil count in BALF also positively cor-
related with the LC3-II expression in lung homogenates, sug-
gesting that autophagy is closely correlated with the severity
of asthma as well as the eosinophilic inflammation. Inhibition
of autophagy by intraperitoneal injection of 3-methyladenine
(3-MA) and intranasal treatment with Atg5 shRNA led to a
significantly improved airway hyperresponsiveness (AHR),
reduced number of eosinophils and IL-5 levels in BALF, as
well as improved histological inflammatory features [118].
However, it cannot be excluded that 3-MA also blocked cy-
tokine signaling events in this model [119, 120]. Finally, in-
tranasal administration of anti-IL-5 monoclonal antibody re-
sulted in reduced LC3-II expression in lung homogenates,
together with improved AHR and decreased eosinophil num-
bers in BALF [118]. Taken together, there is evidence that
autophagy is induced in structural and inflammatory cells of
the lungs in asthma, but it remains unclear how this phenom-
enon contributes to the pathogenesis of asthma. Therefore, it
seems too early to propose novel therapeutic approaches for
the treatment of asthma based on autophagy inhibition.
Chronic rhinosinusitis (CRS)
CRS is characterized by chronic inflammation of the sinonasal
mucosa and clinically associated with sinus pressure, nasal
congestion, and a decreased sense of smell persisting for more
than 12 weeks [121]. CRS is often associated with pro-
nounced eosinophil-dominant infiltration and inflammation
and then classified as eosinophilic chronic rhinosinusitis
(ECRS) [122].
The effect of autophagy on the development of ECRS was
investigated in mice with a conditional knockout ofAtg7with-
inmyeloid cells (mainly neutrophils andmacrophages), which
was mediated using the LyzM-Cre (Lyz2-Cre) recombinase
activity. An established mouse model of ECRS resulted in
significantly increased eosinophil infiltration, epithelial hyper-
plasia, and mucosal thickening in Atg7flox/floxLyzM-Cre mice
as compared with Atg7flox/flox mice, possibly owing to in-
creased prostaglandin (PG) D2 production [123].
Interestingly, eosinophil infiltration and histological abnor-
malities were significantly improved following macrophage
depletion in Atg7flox/floxLyzM-Cre mice with ECRS. The
autophagy-deficient macrophages exacerbate the eosinophilic
inflammation in ECRS, at least partially, through the release
of elevated IL-1β levels. Therefore, results of this study sug-
gest a protective role of macrophage autophagy on eosinophil-
ic inflammation [123].
Eosinophilic esophagitis (EoE)
EoE is defined as a chronic, immune-mediated disorder
resulting in esophageal dysfunction and eosinophil-
predominant inflammation leading to tissue remodeling and
fibrotic stricture [124]. A study performed on a pediatric pa-
tient cohort revealed upregulated ATG7 gene expression in
esophageal biopsies from active EoE patients as compared
with esophagus-healthy control individuals, EoE patients in
remission and patients with gastroesophageal reflux disease
(GERD) [125]. Therefore, ATG7 might be used as a valuable
tissue biomarker of active EoE, and other ATG genes may be
explored to potentially identify novel biomarkers for EoE di-
agnosis, monitoring, and prognosis. A recent study revealed a
possible cytoprotective mechanism of autophagy which sup-
ports cellular redox balance and homeostasis following expo-
sure to the inflammatory EoE environment, providing mech-
anistic insights into the role of autophagy in EoE pathogenesis
[126]. Specifically, TNF-α and IL-13 have been identified as
triggers of autophagy within the epithelium of the esophagus
under in vitro conditions, including an esophageal organoid
model. Inhibition of autophagic flux via chloroquine treatment
augmented basal cell hyperplasia in these model systems.
Moreover, this study has demonstrated increased autophagy
in epithelial cells of the esophagus in EoE patients in vivo
[126]. However, it should be noted that also this study did
not investigated the role of autophagy in eosinophils.
Role of autophagy in eosinophil
differentiation
Understanding the differentiation of eosinophils is crucial
sincemany eosinophilic diseases are associatedwith increased
production of eosinophils in the bonemarrow. Eosinophils are
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continuously produced from eosinophil lineage-committed
progenitors (EoPs) which derive from common myeloid pro-
genitors (CMPs) in human [127] and granulocyte-monocyte
progenitors (GMPs) in mice [128]. Terminally differentiated
eosinophils are no longer mitotically active, and they are re-
leased into the circulation [129]. To keep cellular homeostasis,
it is important that the differentiation process of eosinophils is
tightly controlled [130].
Eosinophil differentiation is regulated by a complex net-
work of transcription factors and extrinsic signals. During
eosinopoiesis, a unique set of dynamic changes in the expres-
sion of transcription factors occurs, among which GATA-1,
PU.1, and C/EBP members are the most critical ones [131,
132]. In addition, RhoH (small atypical GTPase) has been
reported as a negative regulator of eosinophil differentiation,
presumably due to dysregulated GATA-2 expression [133].
XBP1 has been identified as a highly selective and required
transcription factor for eosinophil development [134]. It sup-
ports the survival of cells of the eosinophil lineage in a cell-
intrinsic way while having no effect on basophils or neutro-
phils [134]. IL-5, IL-3, and granulocyte/macrophage colony-
stimulating factor (GM-CSF) are recognized as the most rele-
vant cytokines which stimulate eosinophil differentiation, ac-
tivation, and survival [135]. A recent study implies IL-33 in
the control of various stages of eosinophil differentiation
mainly through the expansion of eosinophil precursors and
upregulation of the IL-5 receptor α (IL-5Rα) on this popula-
tion [136].
Until recently very little was known about the role of au-
tophagy in eosinophils. Two studies investigated the involve-
ment of mechanistic target of rapamycin (mTOR) on eosino-
phil hematopoiesis and asthma pathogenesis [137, 138]. The
mTOR functions as a major nutrient-sensitive regulator of cell
metabolism, balancing many anabolic and catabolic processes
including protein synthesis and autophagy, respectively [44].
mTOR is a serine/threonine protein kinase that forms two
distinct protein complexes, mTORC1 and mTORC2 [44].
Rapamycin selectively inhibits the activity of mTORC1,
resulting in restricted eosinophil differentiation from mouse
bone marrow cells and reduced cytokine production in vitro
[137]. To examine the effect of rapamycin on allergic asthma,
rapamycin was administered in a mouse model of OVA-
induced allergic airway inflammation. Eosinophil numbers
in BALF, peripheral blood, and bone marrow of rapamycin-
treated mice were remarkably decreased, resulting in attenu-
ated allergic airway inflammation and mucus production.
However, rapamycin induced the accumulation of eosinophil
progenitors in the bone marrow [137].
The same group subsequently investigated the function of
mTOR in eosinophil differentiation and asthma pathogenesis
using both genetic and pharmacological approaches.
Treatment with torin-1, an inhibitor of mTORC1 and
mTORC2, resulted in an enhanced in vitro eosinophil
differentiation, as well as an increased size and number of
eosinophil colony-forming units [138]. Similarly, Mtorflox/
floxLyzM-Cre mice with a myeloid-specific knockout of
mTOR exhibited an augmented production of eosinophil pro-
genitors together with deteriorated allergic airway inflamma-
tion after OVA exposure [138]. Collectively, these data dem-
onstrated the differential effects of mTOR in the regulation of
eosinophil development, likely due to the distinct functions of
mTORC1 and mTORC2 [138].
With the purpose of studying the developmental and func-
tional consequences of autophagy deficiency in eosinophils, a
novel mouse model with an eosinophil-specific knockout of
Atg5 was generated (Atg5flox/floxeoCre mice) [120]. Cre
recombinase is expressed only after commitment to the eosin-
ophil lineage and is absolutely specific for eosinophils (eoCre
mice) [22]. Results obtained from Atg5flox/floxeoCre mice
showed elevated numbers of immature eosinophils in the bone
marrow and a significant drop of mature eosinophils in the
circulation [89] (Fig. 2). Knockout of Atg5 within eosinophils
resulted in delayed and reduced eosinophil precursor prolifer-
ation and maturation under in vitro conditions. No abnormal-
ities in cell death were observed in Atg5-knockout eosino-
phils. During in vitro eosinophil differentiation, a reduced
phosphorylation of p38 and p44/42 mitogen-activated protein
kinases (MAPKs) was detected in eosinophil precursors lack-
ing Atg5, which might explain, at least partially, the observed
phenotype. Eosinophil populations were further purified from
the bone marrow of hypereosinophilic II5 (IL-5) transgenic
mice (NJ.1638), showing downregulation of Gata-1,
C/ebpε, Pu.1, and Trib1 transcription factors in the absence
of Atg5, which might reflect the reduced and delayed eosino-
phil differentiation [89]. Moreover, the differentiation poten-
tial of Atg5-knockout eosinophil precursors was tested under
pathologic conditions, employing an establishedmouse model
of chronic eosinophilic leukemia (CEL). CEL has been initi-
ated in mice by the combination of fusion protein FIP1L1-
PDGFRα (F/P) expression and IL-5 overexpression [139],
resulting in a less severe eosinophilia development in the ab-
sence of Atg5. Similar results were obtained in EoL-1 cells, a
model of an established human CEL. Upon induced differen-
tiation of EoL-1 cells, significantly lower levels of surface
markers CD11b, Siglec-8 and CCR3 were observed in
ATG5-knockout EoL-1 cells, indicating decreased maturation
of eosinophil precursors [89] (Fig. 2). These observations sug-
gest that targeting ATG5 within the eosinophil lineage might
represent a possible future treatment of eosinophilic leukemia.
These findings were in contrast with the effect of Atg5-
deficiency on neutrophil differentiation in Atg5flox/floxLyzM-
Cremice [86]. Thesemice exhibited an increased proliferation
and differentiation of Atg5-knockout neutrophils, culminating
in neutrophil accumulation in the circulation and lymphoid
organs. Accelerated neutrophil differentiation was also ob-
served upon shRNA-mediated Atg5 knockdown in Hoxb8
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neutrophils [86]. Furthermore, autophagy was studied in early
granulopoiesis in mice with a conditional deletion of Atg7 at
the hematopoietic stem and progenitor level (Atg7flox/floxVav-
Cre), which caused accumulation of immature neutrophils in
the spleen, blood, and peritoneum [87]. An expanded popula-
tion of immature myeloblasts and myelocyte precursors was
also observed in Atg7flox/floxCebpa-Cre mice, expressing
C/ebpα promotor predominantly at the GMP stage. Atg7-
knockout neutrophil precursors were unable to shift from gly-
colytic activity toward mitochondrial respiration, demonstrat-
ing accumulation of lipid bodies and decreased ATP produc-
tion. Inhibition of autophagy-mediated lipid degradation
failed to provide free fatty acids to support mitochondrial res-
piration and ATP production, resulting in a defective neutro-
phil differentiation [87].
Interestingly, it has been reported that the p38 MAPK ac-
tivity differentially regulates eosinophil and neutrophil differ-
entiation, potentially through the modulation of C/EBPα tran-
scriptional activity [140]. A recent study showed that Trib1
expression favors eosinophil development by restraining
neutrophil lineage commitment by modulating C/EBPα, part-
ly clarifying the regulation of granulocytic lineage selection
and identity [141]. In addition, single-cell transcriptome anal-
ysis has determined two different myeloid progenitor subsets
which separate early in the hematopoietic development.
Subsets can be differentiated according to the presence (eosin-
ophils, mast cells, megakaryocytes, erythrocytes) or absence
(neutrophils, lymphocytes, monocytes) of Gata1 expression
[142]. The potential involvement of autophagy in the segre-
gation and regulation of these two distinct myeloid progenitor-
differentiation pathways has not been established yet and
could be the subject for future studies.
Role of autophagy in eosinophil effector
functions
Activated eosinophils exert their effector functions mainly
through degranulation and formation of eosinophil extracellu-
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Fig. 2. The role of ATG5 in eosinophil differentiation and effector
functions. Atg5-knockout eosinophil precursors with suppressed
autophagy exhibit a delayed and reduced proliferation, maturation, p38
and p44/42 MAPK activation, and a reduced expression of Gata-1,
C/ebpε, Pu.1, and Trib1 transcription factors (TFs). A decrease in
eosinophil differentiation results in reduced numbers of mature
eosinophils in blood and peripheral tissues. The differentiation capacity
of eosinophil precursors in the absence of Atg5/ATG5 is reduced in
established mouse (FIP1L1-PDGFRα; F/P mice) and human eosinophil
leukemia models (EoL-1 cells). Moreover, Atg5-knockout eosinophils
exhibit enhanced degranulation, EET formation, bacterial killing, and
signaling transduction following their activation in vitro. Mice with
Atg5-knockout eosinophils have been shown to better clear a bacterial
infection with C. rodentium. ATG5low-expressing human eosinophils
demonstrate enhanced degranulation abilities in both tissues and blood
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important innate immune effector functions against patho-
gens, they can also cause significant immunopathologies [14].
Degranulation
Eosinophil specific granules are rich in four major cationic
proteins: major basic protein (MBP), eosinophil peroxidase
(EPX), and the ribonucleases eosinophil cationic protein
(ECP) and eosinophil-derived neurotoxin (EDN) [143].
Eosinophils release granule contents into the extracellular
space through three commonly observed pathways, namely,
piecemeal degranulation (PMD), exocytosis, or cytolysis [17].
During PMD, the specific granules are progressively emptied
and eosinophil sombrero vesicles (EoSVs) transfer the select-
ed secretory cargo to plasma membrane [144, 145]. Granules
can release their entire contents following granule fusion with
the plasma membrane in a process called exocytosis, which
can be preceded by intracellular granule-granule fusion [146].
Eosinophil cytolysis is characterized by the disintegration of
cytoplasmic membrane and release of nuclear DNA cloud
together with intact granules, which are deposited in tissues
upon cell lysis [147]. It has been demonstrated that eosinophil
cytolysis is dependent on receptor-interacting protein kinase 3
(RIPK3)-mixed lineage kinase-like (MLKL) signaling path-
way and can be counterregulated by autophagy induction,
perhaps opening up new ways for therapeutic interventions
[148]. PMD and cytolysis have been frequently reported to
be associated with eosinophilic diseases such as asthma, nasal
polyps, IBD, allergic rhinitis, and EoE [149–151]. On the
contrary, exocytosis is rarely documented during inflammato-
ry responses, but has been observed during the interaction of
eosinophils with helminths [152] and certain environmental
fungi [153].
The effect of autophagy on eosinophil degranulation has
been studied in Atg5-knockout eosinophils, which intriguing-
ly exhibited an enhanced capacity to degranulate in vitro as
measured by increased CD63 surface expression following
GM-CSF priming and C5a stimulation [89] (Fig. 2).
Moreover, an experimental in vivo mouse model of bacterial
infection with Citrobacter (C.) rodentium was used to test the
infiltrating colonic eosinophils for their activation and degran-
ulation status. Eosinophils lacking Atg5 exhibited higher
Siglec-F and CD63 surface expression levels, supporting the
in vitro observations [89]. In addition, the expression of
ATG5 in human eosinophils was analyzed together with their
degranulation status in human eosinophilic tissues. Patients
with angiolymphoid hyperplasia, EoE, and sebaceous gland
carcinoma demonstrated a positive correlation between ATG5
expression and intracellular EPX levels in tissue eosinophils,
suggesting increased degranulation in ATG5low-expressing
eosinophils. These data were supported by observations in
hypereosinophilic syndrome (HES) patients, in which a sig-
nificant negative correlation between ATG5 (and ATG7)
mRNA expression in blood eosinophils and secreted EDN
levels in plasma was found [89] (Fig. 2). These data supported
the concept that Atg5-knockout eosinophils in mice and
ATG5low-expressing human eosinophils are more susceptible
to degranulation.
In contrast to eosinophils, autophagy was reported to be
crucial for the degranulation of mouse neutrophils [88] and
mast cells [85]. Mice with autophagy deficiency in myeloid
cell lineage (Atg7flox/floxLyzM-Cre) showed reduced severity
of several neutrophil-mediated inflammatory and autoimmune
disease models, including PMA-induced ear inflammation,
LPS-induced breakdown of blood-brain barrier, and experi-
mental autoimmune encephalomyelitis. The most likely
mechanism was suggested to be a reduced NADPH oxidase-
mediated production of reactive oxygen species (ROS) in
Atg7-knockout neutrophils [88]. These findings suggest that
autophagy has differential effects on eosinophil and neutro-
phil degranulation. It has also been reported that in contrast to
neutrophils, which are absolutely required for antibacterial
defense, pharmacological or genetic ablation of eosinophils
does not result in obvious functional consequences [16].
Extracellular trap (ET) formation
Eosinophils are able to form ETs which consist of mitochon-
drial DNA and cationic granule proteins released from acti-
vated cells [154]. EETs perform antibacterial functions, and
they enable the accumulation of toxic granule proteins directly
onto pathogens captured in the DNA scaffold, limiting the
damage of surrounding host tissues [155]. The formation of
EETs has been demonstrated in various infectious, allergic,
and autoimmune eosinophilic disorders [154, 156–159].
In addition to eosinophils, activated neutrophils are also
able to form similar extracellular DNA structures, known as
neutrophil extracellular traps (NETs) [160, 161]. Interestingly,
the release of mitochondrial DNA does not require cell death
neither does it limit the viability of the granulocytes [161]. On
the other hand, neutrophil death-dependent mechanisms have
also been described, and the scientific dispute regarding the
requirement of cell death for NET formation is ongoing [155].
It has been demonstrated that NET formation by viable neu-
trophils depends on the activity of NADPH oxidase, cytoskel-
eton rearrangements, and glycolytic ATP production [162,
163].
A recent study reported the requirement for autophagy
in the formation of EETs in the airway of asthmatic mice.
Treatment with the autophagy inhibitor 3-MA attenuated
EET formation and improved the lung inflammation, mi-
tochondrial metabolism, and oxidative stress in OVA-
challenged mice [164]. Moreover, treatment of neutrophils
with autophagy inhibitor wortmannin reduced NET forma-
tion by activated neutrophils [165, 166]. 3-MA and
wortmannin have been widely used as autophagy inhibitors
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based on their inhibitory effect on class III PI3K activity,
which is known to be essential for autophagy induction
[50]. The same inhibitors, however, are also reported to
block class I PI3Ks which contribute to the activation of
NADPH oxidase [167–169]. Therefore, decreased forma-
tion of EETs following 3-MA and wortmannin treatment
can also be explained by inhibition of ROS production. A
recent study has investigated this issue in details, and the
reported results suggest that PI3K inhibitors, such as 3-MA
and wortmannin, block both EET and NET formation in an
autophagy-independent manner [120]. In addition, both
Atg5-knockout eosinophils and Atg5-knockout neutrophils
were fully capable to release extracellular DNA after stim-
ulation, demonstrating that autophagy is not required for
both EET and NET formation [120]. A careful quantitative
analysis revealed that Atg5-knockout eosinophils exhibit
an even increased ability of EET formation compared with
control eosinophils in vitro, supporting the surprising find-
ings of augmented degranulation in eosinophils lacking
Atg5 [89]. Eosinophils lacking Atg5 also demonstrated el-
evated in vitro bacterial killing of Escherichia (E.) coli,
suggesting increased effector function of eosinophils in
the absence of Atg5. Moreover, the antibacterial defense
of Atg5-knockout eosinophils was tested under in vivo
conditions in the C. rodentium model. An improved local
and systemic clearance of C. rodentium was observed in
Atg5flox/floxeoCre mice, together with an enhanced ability
to form EETs [89]. Atg5-knockout eosinophils demonstrat-
ed an increased activity of Stat3, p38, and p44/42 signaling
pathways following cytokine stimulation, providing a pos-
sible explanation for enhanced eosinophil effector func-
tions in the absence of Atg5 [89].
Tumor-associated tissue eosinophilia is often observed
in cancer patients and studies suggest their involvement in
tumoricidal activities. Upon interaction with a colorectal
carcinoma cell line Colo-205, eosinophils released their
granule contents such as ECP, EDN, TNF-α, and gran-
zyme A, which exerted cytotoxic responses against tumor
cells [170]. Moreover, ablation of eosinophils severely
compromised antitumor immunity in a colorectal cancer
(CRC) mouse model, most likely owing to impaired Th1
and CD8+ T cell responses. On the other hand, CRC pa-
tients with enhanced eosinophil tumor infiltration demon-
strated robust CD8 T cell infiltrates, resulting in a better
prognosis compared with patients with low-eosinophil in-
filtrating tumors [171]. Interestingly, the blockade of au-
tophagy enhanced T helper 9 (Th9) cell anticancer func-
tions in vivo, and mice with T cell-specific deletion of Atg5
exhibited reduced tumor growth in an IL-9-dependent
manner [172]. Finally, it would be interesting to investi-
gate the functional consequences of Atg5-knockout eosin-
ophils in different disease models and explore their poten-
tial for cancer immunotherapy.
Concluding remarks
The findings summarized in this review article highlight the
autophagic pathway as a protective mechanism of cells which
contributes to the limitation of disease severity in eosinophilic
diseases. Autophagy seems to secure the function of paren-
chymal cells under inflammatory conditions. This process ap-
pears to be particularly important in epithelial cells tomaintain
their barrier function. The generation of conditional/promoter-
specific knockout mice has enabled researcher to investigate
the role of autophagy in a cell-type specific manner. Recently,
such experimental models were also developed to study the
cell-type inherent function of autophagy in eosinophils.
Surprisingly, and in contrast to other immune cells, eosino-
phils enhance effector functions when autophagy is impaired.
Therefore, drug-induced inhibition of autophagy in chronic
inflammatory eosinophilic diseases does not seem to be indi-
cated because of two possible unwanted effects: (1) reduced
epithelial barrier function and (2) increased eosinophil-
mediated immunopathology. In contrast, however, blocking
the autophagic pathway in eosinophils might be beneficial in
eosinophilic tumors. Therefore, pharmacological impairment
of autophagy might also be an option for the therapy of eosin-
ophilic leukemias. Clearly, additional experimental work, in-
cluding the analyses of human cells and tissues, is required to
identify drug targets suitable for the modulation of the autoph-
agic pathway as preventive or therapeutic intervention in eo-
sinophilic diseases and other human pathologies.
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